Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Longitudinal Analysis of Real-World Performance of an Implantable Continuous Glucose Sensor Over Multiple Sensor Insertion and Removal Cycles.

Tweden KS, Deiss D, Rastogi R, Addaguduru S, Kaufman F.

Diabetes Technol Ther. 2019 Nov 7. doi: 10.1089/dia.2019.0342. [Epub ahead of print]

PMID:
31697182
2.

Real-World Safety of an Implantable Continuous Glucose Sensor over Multiple Cycles of Use: A Post-Market Registry Study.

Deiss D, Irace C, Carlson G, Tweden KS, Kaufman F.

Diabetes Technol Ther. 2019 Aug 16. doi: 10.1089/dia.2019.0159. [Epub ahead of print]

PMID:
31418587
3.

Real-World Data from the First U.S. Commercial Users of an Implantable Continuous Glucose Sensor.

Sanchez P, Ghosh-Dastidar S, Tweden KS, Kaufman FR.

Diabetes Technol Ther. 2019 Aug 28. doi: 10.1089/dia.2019.0234. [Epub ahead of print]

PMID:
31385732
4.

Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.

Bosi E, Choudhary P, de Valk HW, Lablanche S, Castañeda J, de Portu S, Da Silva J, Ré R, Vorrink-de Groot L, Shin J, Kaufman FR, Cohen O; SMILE Study Group.

Lancet Diabetes Endocrinol. 2019 Jun;7(6):462-472. doi: 10.1016/S2213-8587(19)30150-0. Epub 2019 Apr 29.

PMID:
31047902
5.

Various AKIP1 expression levels affect its subcellular localization but have no effect on NF-kappaB activation.

Keprová A, Kořínková L, Křížová I, Hadravová R, Kaufman F, Pichová I, Ruml T, Rumlová M.

Physiol Res. 2019 Jun 30;68(3):431-443. Epub 2019 Mar 22.

6.

Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes.

Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, Shulman DI, Bailey TS, Bode BW, Wood MA, Buckingham BA, Kaiserman KB, Shin J, Huang S, Lee SW, Kaufman FR.

Diabetes Technol Ther. 2019 Jan;21(1):11-19. doi: 10.1089/dia.2018.0264. Epub 2018 Dec 26.

7.

In-Clinic Evaluation of the MiniMed 670G System "Suspend Before Low" Feature in Children with Type 1 Diabetes.

Wood MA, Shulman DI, Forlenza GP, Bode BW, Pinhas-Hamiel O, Buckingham BA, Kaiserman KB, Liljenquist DR, Bailey TS, Shin J, Huang S, Chen X, Cordero TL, Lee SW, Kaufman FR.

Diabetes Technol Ther. 2018 Nov;20(11):731-737. doi: 10.1089/dia.2018.0209. Epub 2018 Oct 6.

PMID:
30299976
8.

Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch.

Stone MP, Agrawal P, Chen X, Liu M, Shin J, Cordero TL, Kaufman FR.

Diabetes Technol Ther. 2018 Oct;20(10):689-692. doi: 10.1089/dia.2018.0202. Epub 2018 Aug 30.

PMID:
30160523
9.

Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes.

Slover RH, Tryggestad JB, DiMeglio LA, Fox LA, Bode BW, Bailey TS, Brazg R, Christiansen MP, Sherr JL, Tsalikian E, Kaiserman KB, Sullivan A, Huang S, Shin J, Lee SW, Kaufman FR.

Diabetes Technol Ther. 2018 Sep;20(9):576-584. doi: 10.1089/dia.2018.0109. Epub 2018 Jul 31.

PMID:
30063162
10.

Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled Diabetes.

Bansal M, Shah M, Reilly B, Willman S, Gill M, Kaufman FR.

Appl Health Econ Health Policy. 2018 Oct;16(5):675-684. doi: 10.1007/s40258-018-0398-2.

PMID:
29936685
11.

IMPROVED HBA1C, TOTAL DAILY INSULIN DOSE, AND TREATMENT SATISFACTION WITH INSULIN PUMP THERAPY COMPARED TO MULTIPLE DAILY INSULIN INJECTIONS IN PATIENTS WITH TYPE 2 DIABETES IRRESPECTIVE OF BASELINE C-PEPTIDE LEVELS.

Vigersky RA, Huang S, Cordero TL, Shin J, Lee SW, Chhabra H, Kaufman FR, Cohen O; OpT2mise Study Group.

Endocr Pract. 2018 May;24(5):446-452. doi: 10.4158/EP-2017-0234.

PMID:
29847166
12.

Time trend and regional variability of mortality rate due to ovarian cancer in Brazil: a 15-year analysis.

Schoueri JHM, Kaufman FAA, de Camargo CRS, Sette CVM, Adami F, Figueiredo FWDS.

J Public Health (Oxf). 2018 Dec 1;40(4):e474-e481. doi: 10.1093/pubmed/fdy080.

PMID:
29733385
13.

Sensor-Augmented Pump-Based Customized Mathematical Model for Type 1 Diabetes.

Grosman B, Wu D, Miller D, Lintereur L, Roy A, Parikh N, Kaufman FR.

Diabetes Technol Ther. 2018 Mar;20(3):207-221. doi: 10.1089/dia.2017.0333.

PMID:
29565722
14.

Mutations in the Basic Region of the Mason-Pfizer Monkey Virus Nucleocapsid Protein Affect Reverse Transcription, Genomic RNA Packaging, and the Virus Assembly Site.

Dostálková A, Kaufman F, Křížová I, Kultová A, Strohalmová K, Hadravová R, Ruml T, Rumlová M.

J Virol. 2018 Apr 27;92(10). pii: e00106-18. doi: 10.1128/JVI.00106-18. Print 2018 May 15.

15.

The Effect of Prior Continuous Glucose Monitoring Use on Glycemic Outcomes in the Pivotal Trial of the MiniMed 670G Hybrid Closed-Loop System.

Cordero TL, Garg SK, Brazg R, Bailey TS, Shin J, Lee SW, Kaufman FR.

Diabetes Technol Ther. 2017 Dec;19(12):749-752. doi: 10.1089/dia.2017.0208. Epub 2017 Nov 17.

PMID:
29148821
16.

Clinical and economic benefits of professional CGM among people with type 2 diabetes in the United States: analysis of claims and lab data.

Sierra JA, Shah M, Gill MS, Flores Z, Chawla H, Kaufman FR, Vigersky R.

J Med Econ. 2018 Mar;21(3):225-230. doi: 10.1080/13696998.2017.1390474. Epub 2017 Oct 17.

PMID:
28994334
17.

Re: Castle, et al., 2017; Diabetes Technol Ther; DOI: 10.1089/dia.2017.0012.

Kaufman FR, Shin J.

Diabetes Technol Ther. 2017 Jul;19(7):440. doi: 10.1089/dia.2017.0995. Epub 2017 Jul 13. No abstract available.

PMID:
28704065
18.

Accuracy of a Fourth-Generation Subcutaneous Continuous Glucose Sensor.

Christiansen MP, Garg SK, Brazg R, Bode BW, Bailey TS, Slover RH, Sullivan A, Huang S, Shin J, Lee SW, Kaufman FR.

Diabetes Technol Ther. 2017 Aug;19(8):446-456. doi: 10.1089/dia.2017.0087. Epub 2017 Jul 12.

19.

Automated Insulin Delivery System Nomenclature.

Cohen O, Vigersky RA, Lee SW, Cordero TL, Kaufman FR.

Diabetes Technol Ther. 2017 Jun;19(6):379-380. doi: 10.1089/dia.2017.0073. No abstract available.

PMID:
28613946
20.

Evaluation of a Predictive Low-Glucose Management System In-Clinic.

Buckingham BA, Bailey TS, Christiansen M, Garg S, Weinzimer S, Bode B, Anderson SM, Brazg R, Ly TT, Kaufman FR.

Diabetes Technol Ther. 2017 May;19(5):288-292. doi: 10.1089/dia.2016.0319. Epub 2017 Feb 16.

PMID:
28221823
21.

An Expert Opinion on Advanced Insulin Pump Use in Youth with Type 1 Diabetes.

Bode BW, Kaufman FR, Vint N.

Diabetes Technol Ther. 2017 Mar;19(3):145-154. doi: 10.1089/dia.2016.0354. Epub 2017 Jan 30. Review.

PMID:
28135116
22.

Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes.

Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR.

Diabetes Technol Ther. 2017 Mar;19(3):155-163. doi: 10.1089/dia.2016.0421. Epub 2017 Jan 30.

23.

Effectiveness of Automated Insulin Management Features of the MiniMed® 640G Sensor-Augmented Insulin Pump.

Zhong A, Choudhary P, McMahon C, Agrawal P, Welsh JB, Cordero TL, Kaufman FR.

Diabetes Technol Ther. 2016 Oct;18(10):657-663. Epub 2016 Sep 27.

24.

Economic impact of hypoglycemia among insulin-treated patients with diabetes.

Sussman M, Sierra JA, Garg S, Bode B, Friedman M, Gill M, Kaufman F, Vigersky R, Menzin J.

J Med Econ. 2016 Nov;19(11):1099-1106. Epub 2016 Jul 7.

PMID:
27292016
25.

Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes.

Bergenstal RM, Garg S, Weinzimer SA, Buckingham BA, Bode BW, Tamborlane WV, Kaufman FR.

JAMA. 2016 Oct 4;316(13):1407-1408. doi: 10.1001/jama.2016.11708. No abstract available.

PMID:
27629148
26.

Hybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient Conditions.

Grosman B, Ilany J, Roy A, Kurtz N, Wu D, Parikh N, Voskanyan G, Konvalina N, Mylonas C, Gottlieb R, Kaufman F, Cohen O.

J Diabetes Sci Technol. 2016 May 3;10(3):708-13. doi: 10.1177/1932296816631568. Print 2016 May.

27.

Recent advances in management of the HIV/HCV coinfected patient.

Bednasz CJ, Sawyer JR, Martinez A, Rose PG, Sithole SS, Hamilton HR, Kaufman FS, Venuto CS, Ma Q, Talal A, Morse GD.

Future Virol. 2015;10(8):981-997.

28.

Feasibility of Outpatient 24-Hour Closed-Loop Insulin Delivery.

de Bock MI, Roy A, Cooper MN, Dart JA, Berthold CL, Retterath AJ, Freeman KE, Grosman B, Kurtz N, Kaufman F, Jones TW, Davis EA.

Diabetes Care. 2015 Nov;38(11):e186-7. doi: 10.2337/dc15-1047. Epub 2015 Aug 27. No abstract available.

29.

Project Baiterek: A Patient Access Program to Improve Clinical Outcomes and Quality of Life in Children with Type 1 Diabetes in Kazakhstan.

Muratalina A, Smith-Palmer J, Nurbekova A, Abduakhassova G, Zhubandykova L, Roze S, Karamalis M, Shamshatova G, Demessinov A, D'Agostino ND, Lynch P, Yedigarova L, Klots M, Valentine W, Welsh J, Kaufman F.

Value Health Reg Issues. 2015 Sep;7:74-79. doi: 10.1016/j.vhri.2015.09.002. Epub 2015 Nov 14.

PMID:
29698155
30.

Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery.

Weiss R, Garg SK, Bergenstal RM, Klonoff DC, Bode BW, Bailey TS, Thrasher J, Schwartz F, Welsh JB, Kaufman FR; ASPIRE In-Home Study Group.

J Diabetes Sci Technol. 2015 May 18;9(5):1016-20. doi: 10.1177/1932296815586014.

31.

Retrospective analysis of the real-world use of the threshold suspend feature of sensor-augmented insulin pumps.

Agrawal P, Zhong A, Welsh JB, Shah R, Kaufman FR.

Diabetes Technol Ther. 2015 May;17(5):316-9. doi: 10.1089/dia.2014.0257. Epub 2015 Jan 22.

32.

The effects of lowering nighttime and breakfast glucose levels with sensor-augmented pump therapy on hemoglobin A1c levels in type 1 diabetes.

Maahs DM, Chase HP, Westfall E, Slover R, Huang S, Shin JJ, Kaufman FR, Pyle L, Snell-Bergeon JK.

Diabetes Technol Ther. 2014 May;16(5):284-91. doi: 10.1089/dia.2013.0227. Epub 2014 Jan 22.

PMID:
24450776
33.

The PILGRIM study: in silico modeling of a predictive low glucose management system and feasibility in youth with type 1 diabetes during exercise.

Danne T, Tsioli C, Kordonouri O, Blaesig S, Remus K, Roy A, Keenan B, Lee SW, Kaufman FR.

Diabetes Technol Ther. 2014 Jun;16(6):338-47. doi: 10.1089/dia.2013.0327. Epub 2014 Jan 21.

PMID:
24447074
34.

Hypoglycemia begets hypoglycemia: the order effect in the ASPIRE in-clinic study.

Garg SK, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, Shin J, Welsh JB, Kaufman FR.

Diabetes Technol Ther. 2014 Mar;16(3):125-30. doi: 10.1089/dia.2013.0219. Epub 2014 Jan 9.

PMID:
24405492
35.

Comments on death, posthumous harm and bioethics.

Kaufman F.

J Med Ethics. 2014 Sep;40(9):639-40. doi: 10.1136/medethics-2013-101755. Epub 2013 Dec 17. No abstract available.

PMID:
24345992
36.

Policy and system changes in marketing foods to children.

Katz DL, Fox T, Kaufman FR, Schwartz MB, Wootan MG.

Child Obes. 2013 Dec;9(6):477-83. doi: 10.1089/chi.2013.9605. No abstract available.

PMID:
24320722
37.

Threshold-based insulin-pump interruption for reduction of hypoglycemia.

Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, Ahmann AJ, Welsh JB, Lee SW, Kaufman FR; ASPIRE In-Home Study Group.

N Engl J Med. 2013 Jul 18;369(3):224-32. doi: 10.1056/NEJMoa1303576. Epub 2013 Jun 22.

38.

Model-based sensor-augmented pump therapy.

Grosman B, Voskanyan G, Loutseiko M, Roy A, Mehta A, Kurtz N, Parikh N, Kaufman FR, Mastrototaro JJ, Keenan B.

J Diabetes Sci Technol. 2013 Mar 1;7(2):465-77.

39.

It's time for a standard glucose report from CGM.

Kaufman FR.

Diabetes Technol Ther. 2013 Mar;15(3):197. doi: 10.1089/dia.2013.0061. Epub 2013 Mar 1. No abstract available.

PMID:
23451791
40.

Diabetes care in the school and day care setting.

American Diabetes Association, Clarke W, Deeb LC, Jameson P, Kaufman F, Klingensmith G, Schatz D, Silverstein JH, Siminerio LM.

Diabetes Care. 2013 Jan;36 Suppl 1:S75-9. doi: 10.2337/dc13-S075. No abstract available.

41.

Diabetes screening with hemoglobin A(1c) versus fasting plasma glucose in a multiethnic middle-school cohort.

Buse JB, Kaufman FR, Linder B, Hirst K, El Ghormli L, Willi S; HEALTHY Study Group.

Diabetes Care. 2013 Feb;36(2):429-35. doi: 10.2337/dc12-0295. Epub 2012 Nov 27.

42.

Futures market: Wall Street's thirst for water.

Kaufman F.

Nature. 2012 Oct 25;490(7421):469-71. doi: 10.1038/490469a. No abstract available.

PMID:
23099383
43.

Lessons learned from the HEALTHY primary prevention trial of risk factors for type 2 diabetes in middle school youth.

Marcus MD, Hirst K, Kaufman F, Foster GD, Baranowski T.

Curr Diab Rep. 2013 Feb;13(1):63-71. doi: 10.1007/s11892-012-0333-0. Review.

44.

A clinical trial to maintain glycemic control in youth with type 2 diabetes.

TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, Copeland K, Arslanian S, Cuttler L, Nathan DM, Tollefsen S, Wilfley D, Kaufman F.

N Engl J Med. 2012 Jun 14;366(24):2247-56. doi: 10.1056/NEJMoa1109333. Epub 2012 Apr 29.

45.

User acceptability and perceived benefits of new reports in CareLink Pro 3.0 Therapy Management Software for Diabetes.

Welsh JB, Myers SJ, Uhrinak AN, Kaufman FR, Lee SW.

J Diabetes Sci Technol. 2012 Mar 1;6(2):481-2. No abstract available.

46.

Accuracy of the Sof-sensor glucose sensor with the iPro calibration algorithm.

Welsh JB, Kaufman FR, Lee SW.

J Diabetes Sci Technol. 2012 Mar 1;6(2):475-6. No abstract available.

47.

Cardiovascular risk factors in multi-ethnic middle school students: the HEALTHY primary prevention trial.

Willi SM, Hirst K, Jago R, Buse J, Kaufman F, El Ghormli L, Bassin S, Elliot D, Hale DE; HEALTHY Study Group.

Pediatr Obes. 2012 Jun;7(3):230-9. doi: 10.1111/j.2047-6310.2011.00042.x. Epub 2012 Mar 28.

48.

Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study.

Garg S, Brazg RL, Bailey TS, Buckingham BA, Slover RH, Klonoff DC, Shin J, Welsh JB, Kaufman FR.

Diabetes Technol Ther. 2012 Mar;14(3):205-9. doi: 10.1089/dia.2011.0292. Epub 2012 Feb 8.

PMID:
22316089
49.

Diabetes care in the school and day care setting.

American Diabetes Association, Clarke W, Deeb LC, Jameson P, Kaufman F, Klingensmith G, Schatz D, Silverstein JH, Siminerio LM.

Diabetes Care. 2012 Jan;35 Suppl 1:S76-80. doi: 10.2337/dc12-s076. No abstract available. Erratum in: Diabetes Care. 2012 Apr;35(4):939.

50.

Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump.

Agrawal P, Welsh JB, Kannard B, Askari S, Yang Q, Kaufman FR.

J Diabetes Sci Technol. 2011 Sep 1;5(5):1137-41.

Supplemental Content

Loading ...
Support Center